{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:46:19Z","timestamp":1791506779343,"version":"4.3.4"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of HealthNational Institutes of Health (NIH)","award":["K25 HL125954"],"award-info":[{"award-number":["K25 HL125954"]}]},{"name":"National Institutes of HealthNational Institutes of Health (NIH)","award":["P30 DK089507"],"award-info":[{"award-number":["P30 DK089507"]}]},{"name":"National Institutes of HealthNational Institutes of Health (NIH)","award":["UL1TR000423"],"award-info":[{"award-number":["UL1TR000423"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cysticfibrosisjournal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jcf.2017.01.002","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T08:31:02Z","timestamp":1484901062000},"page":"318-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":115,"title":["Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher"],"prefix":"10.1016","volume":"16","author":[{"given":"Rhonda","family":"Szczesniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya L.","family":"Heltshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Stanojevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jcf.2017.01.002_bb0005","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/oxfordjournals.aje.a008664","article-title":"Determinants of mortality from cystic fibrosis in Canada, 1970\u20131989","volume":"143","author":"Corey","year":"1996","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.002_bb0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.002_bb0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.2009.abs","article-title":"Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition","volume":"32","author":"Kosorok","year":"2001","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2017.01.002_bb0020","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.002_bb0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1513\/pats.200703-040BR","article-title":"Advancing outcome measures for the new era of drug development in cystic fibrosis","volume":"4","author":"Mayer-Hamblett","year":"2007","journal-title":"Proc Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.jcf.2017.01.002_bb0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4155\/cli.11.174","article-title":"Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease","volume":"2","author":"VanDevanter","year":"2012","journal-title":"Clin Investig (Lond)"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.002_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1099-0496(199910)28:4<231::AID-PPUL1>3.0.CO;2-2","article-title":"Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada","volume":"28","author":"Morgan","year":"1999","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.002_bb0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1183\/09031936.00056507","article-title":"From registry to quality management: the German Cystic Fibrosis Quality Assessment project 1995\u20132006","volume":"31","author":"Stern","year":"2008","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.002_bb0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jcf.2009.04.001","article-title":"An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis","volume":"8","author":"Buzzetti","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2017.01.002_bb0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jcf.2009.11.002","article-title":"An overview of international literature from cystic fibrosis registries 2. Neonatal screening and nutrition\/growth","volume":"9","author":"Salvatore","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2017.01.002_bb0055","doi-asserted-by":"crossref","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"Design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"18","key":"10.1016\/j.jcf.2017.01.002_bb0060","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJM199204303261804","article-title":"Prediction of mortality in patients with cystic fibrosis","volume":"326","author":"Kerem","year":"1992","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.002_bb0065","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/thx.52.4.313","article-title":"A prognostic model for the prediction of survival in cystic fibrosis","volume":"52","author":"Hayllar","year":"1997","journal-title":"Thorax"},{"issue":"12 Pt 1","key":"10.1016\/j.jcf.2017.01.002_bb0070","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1164\/rccm.200202-087OC","article-title":"Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality","volume":"166","author":"Mayer-Hamblett","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2017.01.002_bb0075","article-title":"A statistical model to predict one-year risk of death in patients with cystic fibrosis","author":"Aaron","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.002_bb0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcf.2011.08.007","article-title":"Validation of a predictive survival model in Italian patients with cystic fibrosis","volume":"11","author":"Buzzetti","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2017.01.002_bb0085","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200802-327OC","article-title":"Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis","volume":"178","author":"Dasenbrook","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.jcf.2017.01.002_bb0090","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/ppul.20914","article-title":"The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis","volume":"43","author":"Sawicki","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2017.01.002_bb0095","article-title":"Predicting future lung function decline in cystic fibrosis patients: statistical methods and clinical connections","author":"Szczesniak","year":"2015","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.002_bb0100","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0022-3476(97)70025-8","article-title":"Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis","volume":"131","author":"Corey","year":"1997","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jcf.2017.01.002_bb0105","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpeds.2007.03.006","article-title":"Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis","volume":"151","author":"Konstan","year":"2007","journal-title":"J Pediatr"},{"issue":"10","key":"10.1016\/j.jcf.2017.01.002_bb0110","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/thoraxjnl-2011-200953","article-title":"Understanding the natural progression in % FEV1 decline in patients with cystic fibrosis: a longitudinal study","volume":"67","author":"Taylor-Robinson","year":"2012","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.002_bb0115","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jpeds.2008.07.010","article-title":"Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis","volume":"153","author":"Ren","year":"2008","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.002_bb0120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ppul.21388","article-title":"Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis","volume":"46","author":"Konstan","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2017.01.002_bb0125","article-title":"Clinical use of tobramycin inhalation solution (TOBI\u00ae) shows sustained improvement in FEV1 in cystic fibrosis","author":"Konstan","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2017.01.002_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/sim.6845","article-title":"A comparison of change point models with application to longitudinal lung function measurements in children with cystic fibrosis","author":"Moss","year":"2016","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.jcf.2017.01.002_bb0135","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.200702-181OC","article-title":"Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis","volume":"176","author":"Konstan","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.jcf.2017.01.002_bb0140","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.annepidem.2013.08.009","article-title":"A semiparametric approach to estimate rapid lung function decline in cystic fibrosis","volume":"23","author":"Szczesniak","year":"2013","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.jcf.2017.01.002_bb0145","doi-asserted-by":"crossref","DOI":"10.1183\/09031936.00187314","article-title":"Global lung function initiative equations improve interpretation of FEV1 decline among patients with cystic fibrosis","author":"Stanojevic","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2017.01.002_bb0150","article-title":"Forced expiratory volume in 1second variability helps identify patients with cystic fibrosis at risk of greater loss of lung function","author":"Morgan","year":"2015","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.002_bb0155","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jpeds.2014.06.061","article-title":"Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012","volume":"165","author":"VanDevanter","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2017.01.002_bb0160","article-title":"Principled missing data treatments","author":"Lang","year":"2016","journal-title":"Prev Sci"},{"issue":"9","key":"10.1016\/j.jcf.2017.01.002_bb0165","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/sim.1104","article-title":"Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients","volume":"21","author":"Schluchter","year":"2002","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.002_bb0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/rssb.12060","article-title":"Joint modelling of repeated measurements and time-to-event outcomes: flexible model specification and exact likelihood inference","volume":"77","author":"Barrett","year":"2015","journal-title":"J R Stat Soc Series B Stat Methodology"},{"issue":"29","key":"10.1016\/j.jcf.2017.01.002_bb0175","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1002\/sim.5469","article-title":"Jointly modeling the relationship between longitudinal and survival data subject to left truncation with applications to cystic fibrosis","volume":"31","author":"Piccorelli","year":"2012","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.002_bb0180","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/ije\/dyu262","article-title":"Joint modelling of repeated measurement and time-to-event data: an introductory tutorial","volume":"44","author":"Asar","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.002_bb0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00001648-200301000-00014","article-title":"Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation","volume":"14","author":"Rothman","year":"2003","journal-title":"Epidemiology"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.002_bb0190","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jpeds.2008.09.011","article-title":"Patient registry analyses: seize the data, but caveat lector","volume":"153","author":"Schechter","year":"2008","journal-title":"J Pediatr"},{"issue":"S40","key":"10.1016\/j.jcf.2017.01.002_bb0195","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1002\/ppul.23244","article-title":"Tackling the increasing complexity of CF care","volume":"50","author":"Sawicki","year":"2015","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2017.01.002_bb0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1513\/AnnalsATS.201211-108OC","article-title":"Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis","volume":"10","author":"Schechter","year":"2013","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.jcf.2017.01.002_bb0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1513\/AnnalsATS.201209-082OC","article-title":"Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis","volume":"10","author":"VanDyke","year":"2013","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.jcf.2017.01.002_bb0210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ppul.1950150204","article-title":"Pulmonary function between 6 and 18years of age","volume":"15","author":"Wang","year":"1993","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.002_bb0215","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general US population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.002_bb0220","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2017.01.002_bb0225","series-title":"Patient Registry 2015 Annual Report","article-title":"Cystic Fibrosis Foundation","year":"2016"},{"key":"10.1016\/j.jcf.2017.01.002_bb0230","series-title":"UK Cystic Fibrosis Registry 2015 Annual Data Report","article-title":"United Kingdom Cystic Fibrosis Trust","year":"2016"},{"key":"10.1016\/j.jcf.2017.01.002_bb0235","series-title":"The Canadian Cystic Fibrosis Registry 2014 Annual Report","article-title":"Cystic Fibrosis Canada","year":"2016"},{"key":"10.1016\/j.jcf.2017.01.002_bb0240","series-title":"Cystic Fibrosis in Australia 2014: 17th Annual Report","article-title":"Cystic Fibrosis Federation","year":"2016"},{"issue":"7","key":"10.1016\/j.jcf.2017.01.002_bb0245","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1164\/rccm.200410-1335OC","article-title":"Disease-specific reference equations for lung function in patients with cystic fibrosis","volume":"172","author":"Kulich","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.jcf.2017.01.002_bb0250","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.002_bb0255","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcf.2017.01.002_bb0260","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2017.01.002_bb0265","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart","year":"2009","journal-title":"Chest J"},{"issue":"18","key":"10.1016\/j.jcf.2017.01.002_bb0270","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2017.01.002_bb0275","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jcf.2017.01.002_bb0280","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199503303321303","article-title":"Effect of high-dose ibuprofen in patients with cystic fibrosis","volume":"332","author":"Konstan","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcf.2017.01.002_bb0285","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1203\/00006450-199702000-00001","article-title":"Identifying treatments that halt progression of pulmonary disease in cystic fibrosis","volume":"41","author":"Davis","year":"1997","journal-title":"Pediatr Res"},{"issue":"5","key":"10.1016\/j.jcf.2017.01.002_bb0290","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1183\/09031936.00173011","article-title":"Stitching and switching: the impact of discontinuous lung function reference equations","volume":"39","author":"Kirkby","year":"2012","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jcf.2017.01.002_bb0295","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcf.2012.03.009","article-title":"Risk factors for rate of decline in FEV 1 in adults with cystic fibrosis","volume":"11","author":"Konstan","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.002_bb0300","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jpeds.2008.07.011","article-title":"Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use","volume":"153","author":"McPhail","year":"2008","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.002_bb0305","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jcf.2010.04.002","article-title":"Year-to-year changes in lung function in individuals with cystic fibrosis","volume":"9","author":"Liou","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2017.01.002_bb0310","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2017.01.002_bb0315","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"A multicenter, randomized, placebo controlled, double-blind trial of azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.jcf.2017.01.002_bb0320","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.002_bb0325","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.002_bb0330","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcf.2012.11.002","article-title":"Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis","volume":"12","author":"Bilton","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2017.01.002_bb0335","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respir Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919931730005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919931730005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T03:08:26Z","timestamp":1556680106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919931730005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S156919931730005X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2017.01.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2017.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}